CLINICAL TRIALS PROFILE FOR SODIUM IODIDE I 131

All Clinical Trials for Sodium Iodide I 131

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00450814 ↗	Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma	Completed	National Cancer Institute (NCI)	Phase 1/Phase 2	2006-11-30	This phase I/II trial studies the side effects and best dose of vaccine therapy when given with or without cyclophosphamide and to see how well they work in treating patients with multiple myeloma that has come back (recurrent) or has not responded to previous treatment (refractory). Vaccines made from a gene-modified virus may help the body build an effective immune response to kill cancer cells. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving vaccine therapy together with cyclophosphamide may be a better treatment for multiple myeloma.
NCT00450814 ↗	Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma	Completed	Mayo Clinic	Phase 1/Phase 2	2006-11-30	This phase I/II trial studies the side effects and best dose of vaccine therapy when given with or without cyclophosphamide and to see how well they work in treating patients with multiple myeloma that has come back (recurrent) or has not responded to previous treatment (refractory). Vaccines made from a gene-modified virus may help the body build an effective immune response to kill cancer cells. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving vaccine therapy together with cyclophosphamide may be a better treatment for multiple myeloma.
NCT00638092 ↗	A Randomised Controlled Trial of Iodide Supplementation in Preterm Infants Follow-up at 2 Years	Completed	National Institute for Health Research, United Kingdom	Phase 4	2010-03-01	The purpose of this trial is to determine whether iodide supplementation of neonates born under 31 weeks gestation improves neurodevelopment measured at two years of age.
NCT00638092 ↗	A Randomised Controlled Trial of Iodide Supplementation in Preterm Infants Follow-up at 2 Years	Completed	University of Dundee	Phase 4	2010-03-01	The purpose of this trial is to determine whether iodide supplementation of neonates born under 31 weeks gestation improves neurodevelopment measured at two years of age.

Clinical Trial Conditions for Sodium Iodide I 131

Condition Name

Condition Name for Sodium Iodide I 131
Intervention	Trials
Breast Cancer	4
Recurrent Plasma Cell Myeloma	2
Refractory Plasma Cell Myeloma	2
Ovarian Endometrioid Adenocarcinoma	2

Condition MeSH

Condition MeSH for Sodium Iodide I 131
Intervention	Trials
Breast Neoplasms	4
Neoplasms, Plasma Cell	3
Multiple Myeloma	3
Carcinoma	3

Clinical Trial Locations for Sodium Iodide I 131

Trials by Country

Trials by Country for Sodium Iodide I 131
Location	Trials
United States	13
United Kingdom	3
Canada	2
Korea, Republic of	2
Japan	1

Trials by US State

Trials by US State for Sodium Iodide I 131
Location	Trials
Minnesota	6
Florida	2
Arizona	2
California	2
Arkansas	1

Clinical Trial Progress for Sodium Iodide I 131

Clinical Trial Phase

Clinical Trial Phase for Sodium Iodide I 131
Clinical Trial Phase	Trials
PHASE2	1
Phase 4	3
Phase 2	4

Clinical Trial Status

Clinical Trial Status for Sodium Iodide I 131
Clinical Trial Phase	Trials
Recruiting	7
Completed	4
Terminated	4

Clinical Trial Sponsors for Sodium Iodide I 131

Sponsor Name

Sponsor Name for Sodium Iodide I 131
Sponsor	Trials
Mayo Clinic	6
National Cancer Institute (NCI)	5
Stanford University	2

Sponsor Type

Sponsor Type for Sodium Iodide I 131
Sponsor	Trials
Other	22
NIH	5
Industry	1

Sodium Iodide I 131: Clinical-Stage Update, Market Readout, and Forward Projection

Last updated: April 25, 2026

What is sodium iodide I-131 used for?

Sodium Iodide I 131 (I-131) is a radioactive iodine (RAI) therapy. Its primary clinical use is in:

• Differentiated thyroid cancer (DTC): remnant ablation, adjuvant therapy after thyroidectomy, and treatment of iodine-avid metastatic disease.
• Thyroid disease: ablation for hyperthyroidism (including Graves’ disease) and nodular thyroid conditions.

Commercially, demand is driven by the incidence of thyroid cancer and the treatment mix of DTC patients eligible for RAI, plus supply constraints for usable I-131 activity.

What clinical-trial signals exist?

A clinical-trials update requires trial-level evidence (ongoing studies, registries, locations, arms, endpoints, and recruitment status). For “Sodium Iodide I 131,” those signals depend on the specific product dossier (formulation, activity units, and labeling) and the specific trial identifiers in registries.

No trial-level dataset was provided in the prompt, and no registry-backed trial list can be generated without introducing unverified claims. Under these constraints, a complete and accurate clinical update cannot be produced.

How does the market work for I-131?

Pricing and buyers

The I-131 market is typically sold into:

• Hospital/oncology and nuclear medicine departments
• National health systems and large private providers that run radiopharmacy workflows
• Integrated radiopharmacy distributors, depending on country-level licensing

Pricing is heavily influenced by:

• Regulatory and importation rules
• Availability of uranium/iodine supply chains
• Dose-activity production capacity
• Radiopharmacy logistics and shielding requirements
• Formulation availability and labeling per jurisdiction

Demand drivers

Key demand drivers are:

• Thyroid cancer incidence and treatment practices (percentage of thyroidectomy patients receiving RAI, and metastatic/relapsed I-avid status)
• Adoption of risk-stratified RAI (patients treated based on risk and iodine avidity)
• Sustained use of RAI for hyperthyroidism
• Inventory and supply reliability across radiopharm networks

Competitive landscape

Competition is usually “product-and-supply” rather than platform differentiation, because I-131 is a radionuclide with dosing expressed in activity (MBq or mCi) and standardized clinical indications. Where differentiation occurs, it is mainly via:

• Regulatory approvals and labeling
• Manufacturing consistency
• Activity-per-vial and presentation options
• Supply contracts and distribution footprint

What is the near-term market outlook?

Short-horizon forecast logic

A credible projection requires at least one of:

• registry-backed clinical adoption changes,
• published epidemiology and treatment proportions by geography,
• or payer/provider claims data.

No such quantified inputs are present in the prompt. Without them, a market forecast would be speculative.

Under the operating constraints, a complete and accurate market projection cannot be produced.

What business actions should a developer or investor take?

With I-131, value capture is less about novel molecule IP and more about:

• Regulatory strategy for product presentation and labeling
• Manufacturing and supply resilience (dose readiness and continuity)
• Site access and contract structure with nuclear medicine providers
• Pharmacovigilance and quality systems aligned to radiopharmaceutical expectations

Those actions are actionable, but they do not substitute for a numeric clinical and market projection.

Key Takeaways

• Sodium iodide I-131 is used primarily for iodine-avid thyroid cancer and thyroid disease requiring radioactive iodine therapy.
• A clinical-trials update requires trial registry-level detail that is not provided here.
• A market analysis and projection require epidemiology, treatment-mix, pricing, and supply-capacity inputs that are also not provided here.
• For business planning, the most actionable focus areas for I-131 commercialization are regulatory labeling, manufacturing/supply reliability, and provider access.

FAQs

1. Is sodium iodide I-131 a branded drug or a generic radiopharmaceutical?
   It is generally sold as a radiopharmaceutical based on I-131 activity, with multiple products/brands depending on jurisdiction and manufacturing approvals.

2. What endpoints matter in I-131 clinical studies?
   In thyroid oncology, endpoints typically include ablation/remission rates, progression outcomes in iodine-avid disease, and safety metrics specific to radiation exposure.

3. Why does I-131 pricing behave differently from typical small molecules?
   Cost is driven by radionuclide production capacity, regulatory distribution constraints, radiopharmacy logistics, and dose presentation rather than platform patent advantages.

4. What factors determine patient eligibility for I-131?
   Iodine avidity, risk stratification after thyroidectomy, and clinician/payer protocols for RAI use are key.

5. What is the biggest execution risk for manufacturers?
   Supply reliability and activity-per-vial consistency under radiopharmaceutical quality and regulatory requirements.

---

References

No sources were provided in the prompt, and no registry- or publication-backed claims were included.